Bokf Na Buys 6,024 Shares of Zoetis Inc. (NYSE:ZTS)

Bokf Na lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 10.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 64,623 shares of the company’s stock after acquiring an additional 6,024 shares during the quarter. Bokf Na’s holdings in Zoetis were worth $10,554,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Callahan Advisors LLC increased its stake in shares of Zoetis by 90.4% in the fourth quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock worth $2,135,000 after purchasing an additional 6,221 shares in the last quarter. CIBC Asset Management Inc boosted its holdings in Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock worth $38,617,000 after buying an additional 46,050 shares during the period. Schroder Investment Management Group increased its stake in Zoetis by 2.6% in the 4th quarter. Schroder Investment Management Group now owns 245,726 shares of the company’s stock worth $40,036,000 after buying an additional 6,169 shares in the last quarter. PFW Advisors LLC bought a new stake in Zoetis during the fourth quarter valued at about $1,764,000. Finally, Vanguard Group Inc. lifted its position in shares of Zoetis by 0.3% in the fourth quarter. Vanguard Group Inc. now owns 41,366,877 shares of the company’s stock valued at $6,739,905,000 after acquiring an additional 120,158 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Trading Down 5.2 %

Shares of NYSE ZTS opened at $149.82 on Wednesday. Zoetis Inc. has a 1-year low of $139.70 and a 1-year high of $200.33. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.75 and a quick ratio of 1.08. The business’s 50 day moving average is $157.87 and its two-hundred day moving average is $166.69. The stock has a market capitalization of $66.85 billion, a P/E ratio of 27.39, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.38 EPS. As a group, research analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.33%. Zoetis’s dividend payout ratio (DPR) is presently 36.56%.

Insider Buying and Selling

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now directly owns 15,781 shares in the company, valued at approximately $2,682,770. This represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. The trade was a 9.71 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 1,862 shares of company stock valued at $312,254. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ZTS. Barclays increased their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a research report on Friday, February 14th. Piper Sandler boosted their target price on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. Stifel Nicolaus cut their target price on shares of Zoetis from $180.00 to $165.00 and set a “buy” rating for the company in a research note on Monday, April 14th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Finally, Morgan Stanley cut their price objective on Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $216.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.